Medicinal product name Rixathon
Biosimilar medicine
Pharmaceutical form Concentrate for solution for infusion
Strength 500 mg 
Information from the MAH on shortages Not notified
Legal status Rx Prescription (Pr.II stac.)
Summary of product characteristics, package leaflet and labeling text  Summary of product characteristics, patient information leaflet and labeling text approved by the European Medicines Agency is available on European Medicines Agency website
Risk minimisation measuresIzglītojošie materiāli ārstam Izglītojošie materiāli ārstam
Izglītojošie materiāli pacientam Izglītojošie materiāli pacientam
ATC code L01FA01 Antineoplastic agents

Medicinal products (1)

Availability of medicinal product Wholesalers Package size, content Primary packaging Maximum admissible pharmacy price (€ incl. VAT) Product No. Labelling
 Not available (according to the information provided by wholesalers) currently no information on availability from any wholesaler N2
(500 mg/50 ml)
Glass vial    EU/1/17/1185/004  Summary of product characteristics, patient information leaflet and labeling text approved by the European Medicines Agency is available on European Medicines Agency website

Registration information

Marketing authorisation No. EU/1/17/1185/004
Date of authorisation Jun 15, 2017
Marketing authorisation holder, country Sandoz GmbH, Austria